TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
Frequently asked questions
What sector does TMS Co. Ltd. (4891) operate in?
TMS Co. Ltd. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TMS Co. Ltd. (4891) current stock price?
As of the latest data, TMS Co. Ltd. stock price is ¥132, with a previous close of ¥132.
What is TMS Co. Ltd. (4891) current market capitalization?
TMS Co. Ltd. market cap is approximately 6.12 billion.
What is TMS Co. Ltd. (4891) Earnings Per Share (EPS)?
The trailing EPS is -¥16.
What is TMS Co. Ltd. (4891) EBITDA?
TMS Co. Ltd. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -188.59 million.
Does TMS Co. Ltd. (4891) pay dividends?
No. TMS Co. Ltd. does not pay a dividend.
When is TMS Co. Ltd. (4891) next earnings report?
TMS Co. Ltd. is expected to release its next earnings report on February 28, 2026.
What is TMS Co. Ltd. (4891) beta (volatility) score?
TMS Co. Ltd. has a beta of 0.527, indicating lower volatility than the overall market.
